OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MTLF$278.8055

Matricelf Ltd

Biotechnology & Medical ResearchVerified

Matricelf operates with a fully diluted share count of 29.24 million shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution pressure from stock options or convertible instruments. The company's market price of 278.8 ILS results in a market capitalization of approximately 8.15 billion ILS, but no liquidity metrics are available due to the absence of balance-sheet inputs and lack of going-concern language in source documents. Profitability and return metrics are not available for Matricelf, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. Without these metrics, it is not possible to compare the company's performance to industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown or geographic distribution is provided, making it difficult to assess the diversification of its revenue streams. Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or forward-looking revenue guidance for the current or next fiscal year. Historical revenue data is not included in the input, limiting the ability to assess growth trends. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The company is flagged for potential liquidity risk, but no specific risk severities or composite risk scores are available. Recent events, including filings or transcripts, are not disclosed in the input data. No specific recent developments or disclosures are available to inform the company's current strategic or operational status.

30-day price · MTLF-93.80 (-25.8%)
Low$212.00High$378.00Close$269.10As of17 May, 00:00 UTC
Profile
CompanyMatricelf Ltd
TickerMTLF.TA
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Matricelf Ltd is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions for medical applications.

Classification. Matricelf is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.

Matricelf operates with a fully diluted share count of 29.24 million shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution pressure from stock options or convertible instruments. The company's market price of 278.8 ILS results in a market capitalization of approximately 8.15 billion ILS, but no liquidity metrics are available due to the absence of balance-sheet inputs and lack of going-concern language in source documents. Profitability and return metrics are not available for Matricelf, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. Without these metrics, it is not possible to compare the company's performance to industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown or geographic distribution is provided, making it difficult to assess the diversification of its revenue streams. Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or forward-looking revenue guidance for the current or next fiscal year. Historical revenue data is not included in the input, limiting the ability to assess growth trends. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The company is flagged for potential liquidity risk, but no specific risk severities or composite risk scores are available. Recent events, including filings or transcripts, are not disclosed in the input data. No specific recent developments or disclosures are available to inform the company's current strategic or operational status.
Key takeaways
  • Matricelf operates in the healthcare diagnostics segment with a focus on biotechnology.
  • The company has no immediate dilution pressure, as basic and diluted shares are equal.
  • No liquidity metrics are available, and liquidity risk could not be assessed.
  • Profitability and return metrics are not disclosed, limiting performance comparisons.
  • Revenue concentration and geographic exposure are not provided in the available data.
  • Growth trajectory and recent events are not disclosed, limiting forward-looking visibility.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyILS
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$16.1M-$16.3M-$18.2M
FY-3-$12.6M-$12.5M-$12.3M
FY-2-$14.7M-$13.8M-$13.6M
FY-1-$16.1M-$15.6M-$14.8M
FY0-$18.3M-$27.8M-$27.4M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$28.9M$26.2M$22.4M
FY-3$39.5M$35.8M$2.0M
FY-2$30.2M$26.8M$2.5M
FY-1$18.4M$15.2M$86.0k
FY0$27.9M$10.1M$17.4M
PeriodOCFCapExFCFSBC
FY-4-$6.6M-$2.4M-$18.2M
FY-3-$8.3M-$602.0k-$12.3M
FY-2-$10.5M-$616.0k-$13.6M
FY-1-$11.8M-$243.0k-$14.8M
FY0-$14.8M-$597.0k-$27.4M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price$278.80
Market cap$8.15B
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricMTLFActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity1.2% medp25 0.0% · p75 17.4%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 06:29 UTC#fcff8077
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 16:10 UTCJob: 6154b4f2